Pharmacogenetic determinants of anti-cancer drug activity and toxicity
- 1 August 2001
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 22 (8) , 420-426
- https://doi.org/10.1016/s0165-6147(00)01742-9
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapyCancer, 2000
- Recent advances in research on multistage tumorigenesisBritish Journal of Cancer, 2000
- Pharmacogenetics and the practice of medicineNature, 2000
- Correlation of Drug Response with the ATP Tumorchemosensitivity Assay in Primary FIGO Stage III Ovarian CancerGynecologic Oncology, 2000
- The Impact of Genomics-Based Technologies on Drug Safety EvaluationAnnual Review of Pharmacology and Toxicology, 2000
- Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced CancerJournal of Clinical Oncology, 2000
- Pharmacogenomics: Translating Functional Genomics into Rational TherapeuticsScience, 1999
- Gene expression profiling, genetic networks, and cellular states: an integrating concept for tumorigenesis and drug discoveryJournal of Molecular Medicine, 1999
- Review of the Efficacy of Individualized Chemotherapy Selected by In Vitro Drug Sensitivity Testing for Patients With CancerJournal of Clinical Oncology, 1999
- Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemiaThe Lancet, 1991